Holen Sie sich die Stockscreener-App
1.33
3.91%
0.05
Handel nachbörslich:
1.33
Schlusskurs vom Vortag:
$1.28
Offen:
$1.28
24-Stunden-Volumen:
1.42M
Relative Volume:
1.24
Marktkapitalisierung:
$142.47M
Einnahmen:
$32.29M
Nettoeinkommen (Verlust:
$-39.12M
KGV:
-3.625
EPS:
-0.3669
Netto-Cashflow:
$-29.51M
1W Leistung:
+9.47%
1M Leistung:
+15.65%
6M Leistung:
-6.99%
1J Leistung:
-41.67%
1-Tages-Spanne:
$1.28
$1.35
1-Wochen-Bereich:
$1.213
$1.35
52-Wochen-Spanne:
$0.6434
$2.37
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.33 | 142.47M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
Price to earnings forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
MaxCyte Inc focuses on cell engineering. Nasdaq-listed MXCT targets long-term growth - ad-hoc-news.de
Enterprise value to EBITDA forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MaxCyte stock leans on platform demand. Nasdaq listing stays central. - ad-hoc-news.de
Price to sales forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Enterprise value to revenue forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Price to book forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MYE0 Forecast — Price Target — Prediction for 2027 - TradingView
MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT) - TradingView
MXCT Forecast — Price Target — Prediction for 2027 - TradingView
MaxCyte Inc (MXCT) Institutional Confidence - TradingKey
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Business Wire
Form 4 MaxCyte Inc For: 22 June By Investing.com - Investing.com South Africa
MaxCyte (MXCT) grants RSUs and stock options to director - Stock Titan
MaxCyte (MXCT) director awarded RSUs and stock options in annual grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and options in annual equity grant - Stock Titan
MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award - Stock Titan
MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant - Stock Titan
MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants - Stock Titan
MaxCyte (MXCT) director receives RSU and stock option grant - Stock Titan
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
MaxCyte Stockchart levels and volatility on a quiet news day - Ad-hoc-news.de
MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MaxCyte, Inc. (MXCT) Announces Results of Shareholder Vote and Audit Firm Ratification – June 17, 2026 - Minichart
MaxCyte shareholders elect directors and approve auditor at annual meeting - Investing.com
MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com Nigeria
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MaxCyte Inc (MXCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MaxCyte Shareholders Reelect Directors and Ratify Auditor - TipRanks
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MaxCyte Inc (MXCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
MaxCyte Inc (MXCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery - The Globe and Mail
MaxCyte (NASDAQ: MXCT) investors reelect board and ratify auditor - Stock Titan
MaxCyte regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com Canada
MaxCyte regains compliance with Nasdaq minimum bid price rule - Investing.com
MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
MaxCyte (NASDAQ: MXCT) restores Nasdaq minimum bid-price compliance after warning - Stock Titan
MXCT Q1 2026 Earnings: Strong EPS Beat Drives Positive Stock ReactionDividend Increase Stocks - dars.gov.et
MXCT Q1 2026 Earnings: EPS Beats Estimates by Wide Margin, But Revenue Details WithheldConsensus Forecast Report - dars.gov.et
MXCT Q1 2026 Earnings: EPS Surprises Strongly to the Upside, Beating Estimates by 50.98%Revenue Inflection Point - newsline.com
MaxCyte Inc. (MXCT) Posts 3.4% Gain, Testing Resistance at $1.27Entry Point Alerts - newsline.com
MaxCyte (MXCT) Edges Higher on Increased Activity, Tests Key Resistance at $1.27Stop Hunt - The Legal Advocate
MaxCyte Inc. (MXCT) Surges 9.7%: Testing Key Resistance at $1.25Breakout Stock Alerts - The Legal Advocate
MaxCyte Inc. (MXCT) Surges 7.87% as Shares Test Key Resistance LevelMomentum Surge Alerts - The Legal Advocate
MXCT Q1 2026 Earnings: EPS Surprise Beats Estimates by 51%, Shares Rally 8%Earnings Volatility Report - dars.gov.et
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):